Natalizumab therapy of multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 30, Issue 10, 2010, Pages 787-789

  Hutchinson, Michael ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; MITOXANTRONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; PLACEBO; STEROID;

ADD ON THERAPY; AGED; AXONAL INJURY; BRAIN DAMAGE; CELL DAMAGE; CELL DISRUPTION; CLINICAL TRIAL; DEMYELINATION; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; EXON; GASTROENTERITIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFLAMMATION; LEUKOCYTE ACTIVATION; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMOCYSTIS CARINII; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK REDUCTION; SIDE EFFECT; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; HUMANS; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 77957362169     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0088     Document Type: Review

References (13)

1. EMEA guidelines. 2010. Available at www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/000603/human-med-001119.jsp&murl=menus/ medicines/medicines.jsp&mid=WC0b01ac058001d124. Accessed 28 August 2010.
2. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC 2008. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology '71(10):766-773.
3. Khatri BO, Man S, Giovannoni G., Koo AP, Lee JC, Tucky B, Lynn F., Jurgensen S, Woodworth J, Goelz S, Duda PW, Panzara MA, Ransohoff RM, Fox RJ. 2009. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology '72(5):402-409.
4. Kleinschmidt-DeMasters B.K., Tyler KL 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med '353(4):369-374.
5. Lobb RR, Hemler ME 1994. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest '94:1722-1728.
6. Major EO. 2009. Reemergence of PML in natalizumab-treated patients - new cases, same concerns. N Engl J Med '361(11): 1041-1043.
7. Oturai AB, Koch-Henriksen N, Petersen T., Jensen PE, Sellebjerg F, Sorensen PS 2009. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol '16:420-423.
8. Polman CH, O'Connor PW, Havrdova E, Hutchinson M., Kappos L, Miller DH, Phillips J.T., Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med '354(9):899-910.
9. Putzki N, Kollia K, Woods S., Igwe E, Diener HC, Limmroth V. 2009. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol '16:424-426.
10. Rudick RA, Stuart WH, Calabresi P.A., Confavreux C., Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn D.R., Lynn F., Panzara MA, Sandrock AW; SENTINEL Investigators. 2006. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med '354(9):911-923.
11. Wenning W, Haghikia A, Laubenberger J., Clifford DB, Behrens PF, Chan A, Gold R. 2009. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med '361(11):1075-1080.
12. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature '356:63-66.
13. Yousry TA, Major EO, Ryschkewitsch C, Fahle G., Fischer S, Hou J, Curfman B., Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med '354(9):924-933.